Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Correction of a splicing defect in a mouse model of congenital muscular dystrophy type 1A using a homology-directed-repair-independent mechanism

Abstract

Splice-site defects account for about 10% of pathogenic mutations that cause Mendelian diseases1. Prevalence is higher in neuromuscular disorders (NMDs)2, owing to the unusually large size and multi-exonic nature of genes encoding muscle structural proteins. Therapeutic genome editing to correct disease-causing splice-site mutations has been accomplished only through the homology-directed repair pathway3,4,5, which is extremely inefficient in postmitotic tissues such as skeletal muscle6. Here we describe a strategy using nonhomologous end-joining (NHEJ) to correct a pathogenic splice-site mutation. As a proof of principle, we focus on congenital muscular dystrophy type 1A (MDC1A), which is characterized by severe muscle wasting and paralysis7. Specifically, we correct a splice-site mutation that causes the exclusion of exon 2 from Lama2 mRNA and the truncation of Lama2 protein in the dy2J/dy2J mouse model of MDC1A8. Through systemic delivery of adeno-associated virus (AAV) carrying clustered regularly interspaced short palindromic repeats (CRISPR)–Cas9 genome-editing components, we simultaneously excise an intronic region containing the mutation and create a functional donor splice site through NHEJ. This strategy leads to the inclusion of exon 2 in the Lama2 transcript and restoration of full-length Lama2 protein. Treated dy2J/dy2J mice display substantial improvement in muscle histopathology and function without signs of paralysis.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: An HDR-independent strategy for correcting a Lama2 splicing defect.
Figure 2: Restoration of full-length Lama2 and improvement of muscle pathology following intramuscular AAV9–CRISPR administration in adult dy2J/dy2J mice.
Figure 3: Intraperitoneal administration of AAV9-CRISPR in neonatal dy2J/dy2J.
Figure 4: Temporal-vein administration of AAV9-CRISPR in neonatal dy2J/dy2J mice.

References

  1. 1

    Scotti, M.M. & Swanson, M.S. RNA mis-splicing in disease. Nat. Rev. Genet. 17, 19–32 (2016).

    CAS  Article  Google Scholar 

  2. 2

    Bladen, C.L. et al. The TREAT-NMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy mutations. Hum. Mutat. 36, 395–402 (2015).

    CAS  Article  Google Scholar 

  3. 3

    Yang, Y. et al. A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice. Nat. Biotechnol. 34, 334–338 (2016).

    CAS  Article  Google Scholar 

  4. 4

    Yin, H. et al. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat. Biotechnol. 32, 551–553 (2014).

    CAS  Article  Google Scholar 

  5. 5

    Yin, H. et al. Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo. Nat. Biotechnol. 34, 328–333 (2016).

    CAS  Article  Google Scholar 

  6. 6

    Vahidi Ferdousi, L. et al. More efficient repair of DNA double-strand breaks in skeletal muscle stem cells compared to their committed progeny. Stem Cell Res. 13 3 Pt A, 492–507 (2014).

    CAS  Article  Google Scholar 

  7. 7

    Durbeej, M. Laminin-α2 chain-deficient congenital muscular dystrophy: pathophysiology and development of treatment. Curr. Top. Membr. 76, 31–60 (2015).

    Article  Google Scholar 

  8. 8

    Sunada, Y., Bernier, S.M., Utani, A., Yamada, Y. & Campbell, K.P. Identification of a novel mutant transcript of laminin alpha 2 chain gene responsible for muscular dystrophy and dysmyelination in dy2J mice. Hum. Mol. Genet. 4, 1055–1061 (1995).

    CAS  Article  Google Scholar 

  9. 9

    Geranmayeh, F. et al. Genotype-phenotype correlation in a large population of muscular dystrophy patients with LAMA2 mutations. Neuromuscul. Disord. 20, 241–250 (2010).

    Article  Google Scholar 

  10. 10

    Guiraud, S. et al. The pathogenesis and therapy of muscular dystrophies. Annu. Rev. Genomics Hum. Genet. 16, 281–308 (2015).

    CAS  Article  Google Scholar 

  11. 11

    Stenson, P.D. et al. The Human Gene Mutation Database: building a comprehensive mutation repository for clinical and molecular genetics, diagnostic testing and personalized genomic medicine. Hum. Genet. 133, 1–9 (2014).

    CAS  Article  Google Scholar 

  12. 12

    Xu, H., Wu, X.R., Wewer, U.M. & Engvall, E. Murine muscular dystrophy caused by a mutation in the laminin alpha 2 (Lama2) gene. Nat. Genet. 8, 297–302 (1994).

    CAS  Article  Google Scholar 

  13. 13

    Jinek, M. et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816–821 (2012).

    CAS  Article  Google Scholar 

  14. 14

    Ran, F.A. et al. In vivo genome editing using Staphylococcus aureus Cas9. Nature 520, 186–191 (2015).

    CAS  Article  Google Scholar 

  15. 15

    Roca, X., Krainer, A.R. & Eperon, I.C. Pick one, but be quick: 5′ splice sites and the problems of too many choices. Genes Dev. 27, 129–144 (2013).

    CAS  Article  Google Scholar 

  16. 16

    Kuang, W. et al. Merosin-deficient congenital muscular dystrophy. Partial genetic correction in two mouse models. J. Clin. Invest. 102, 844–852 (1998).

    CAS  Article  Google Scholar 

  17. 17

    Tanguy, Y. et al. Systemic AAVrh10 provides higher transgene expression than AAV9 in the brain and the spinal cord of neonatal mice. Front. Mol. Neurosci. 8, 36 (2015).

    Article  Google Scholar 

  18. 18

    Zincarelli, C., Soltys, S., Rengo, G. & Rabinowitz, J.E. Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol. Ther. 16, 1073–1080 (2008).

    CAS  Article  Google Scholar 

  19. 19

    Gombash Lampe, S.E., Kaspar, B.K. & Foust, K.D. Intravenous injections in neonatal mice. J. Vis. Exp. 93, e52037 (2014).

    Google Scholar 

  20. 20

    Yu, Q. et al. Omigapil treatment decreases fibrosis and improves respiratory rate in dy(2J) mouse model of congenital muscular dystrophy. PLoS One 8, e65468 (2013).

    CAS  Article  Google Scholar 

  21. 21

    Tatem, K.S. et al. Behavioral and locomotor measurements using an open field activity monitoring system for skeletal muscle diseases. J. Vis. Exp. 91, 51785 (2014).

    Google Scholar 

  22. 22

    Iyer, S.R., Valencia, A.P., Hernández-Ochoa, E.O. & Lovering, R.M. In vivo assessment of muscle contractility in animal studies. Methods Mol. Biol. 1460, 293–307 (2016).

    Article  Google Scholar 

  23. 23

    Call, J.A. & Lowe, D.A. Eccentric contraction-induced muscle injury: reproducible, quantitative, physiological models to impair skeletal muscle's capacity to generate force. Methods Mol. Biol. 1460, 3–18 (2016).

    Article  Google Scholar 

  24. 24

    Hendel, A. et al. Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells. Nat. Biotechnol. 33, 985–989 (2015).

    CAS  Article  Google Scholar 

  25. 25

    Tsai, S.Q. et al. GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. Nat. Biotechnol. 33, 187–197 (2015).

    CAS  Article  Google Scholar 

  26. 26

    Hirano, H. et al. Structure and engineering of Francisella novicida Cas9. Cell 164, 950–961 (2016).

    CAS  Article  Google Scholar 

  27. 27

    Kim, E. et al. In vivo genome editing with a small Cas9 orthologue derived from Campylobacter jejuni. Nat. Commun. 8, 14500 (2017).

    CAS  Article  Google Scholar 

  28. 28

    Kleinstiver, B.P. et al. Broadening the targeting range of Staphylococcus aureus CRISPR-Cas9 by modifying PAM recognition. Nat. Biotechnol. 33, 1293–1298 (2015).

    CAS  Article  Google Scholar 

  29. 29

    Kleinstiver, B.P. et al. Engineered CRISPR-Cas9 nucleases with altered PAM specificities. Nature 523, 481–485 (2015).

    Article  Google Scholar 

  30. 30

    Yeo, G. & Burge, C.B. Maximum entropy modeling of short sequence motifs with applications to RNA splicing signals. J. Comput. Biol. 11, 377–394 (2004).

    CAS  Article  Google Scholar 

  31. 31

    Roca, X. et al. Widespread recognition of 5′ splice sites by noncanonical base-pairing to U1 snRNA involving bulged nucleotides. Genes Dev. 26, 1098–1109 (2012).

    CAS  Article  Google Scholar 

  32. 32

    Tan, J. et al. Noncanonical registers and base pairs in human 5′ splice-site selection. Nucleic Acids Res. 44, 3908–3921 (2016).

    CAS  Article  Google Scholar 

  33. 33

    Kemaladewi, D.U. et al. Cell-type specific regulation of myostatin signaling. FASEB J. 26, 1462–1472 (2012).

    CAS  Article  Google Scholar 

  34. 34

    Vilquin, J.T. et al. Identification of homozygous and heterozygous dy2J mice by PCR. Neuromuscul. Disord. 10, 59–62 (2000).

    CAS  Article  Google Scholar 

  35. 35

    Hsu, P.D., Lander, E.S. & Zhang, F. Development and applications of CRISPR-Cas9 for genome engineering. Cell 157, 1262–1278 (2014).

    CAS  Article  Google Scholar 

  36. 36

    Wojtal, D. et al. Spell checking nature: versatility of CRISPR/Cas9 for developing treatments for inherited disorders. Am. J. Hum. Genet. 98, 90–101 (2016).

    CAS  Article  Google Scholar 

  37. 37

    Cong, L. et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819–823 (2013).

    CAS  Article  Google Scholar 

  38. 38

    Mali, P., Esvelt, K.M. & Church, G.M. Cas9 as a versatile tool for engineering biology. Nat. Methods 10, 957–963 (2013).

    CAS  Article  Google Scholar 

  39. 39

    Jian, X., Boerwinkle, E. & Liu, X. In silico prediction of splice-altering single nucleotide variants in the human genome. Nucleic Acids Res. 42, 13534–13544 (2014).

    CAS  Article  Google Scholar 

  40. 40

    LeCun, Y., Bengio, Y. & Hinton, G. Deep learning. Nature 521, 436–444 (2015).

    CAS  Article  Google Scholar 

Download references

Acknowledgements

The Cohn lab members are gratefully acknowledged for their technical support and critical input in this study. We thank I. Vukobradovic and A. Fleniken (Clinical Phenotyping Core, Toronto Centre for Phenogenomics), C. Rand (Aurora Scientific), and M. Justice, J. Dowling, and J. Ruston (Genetics and Genome Biology) for their critical inputs to this study. T. Paton, S. Perreira, G. Casallo, B. Thiruvahindrapuram, W. Sung (Toronto Center for Applied Genomics), and A. Cui (Deep Genomics) are acknowledged for their support in genomic and bioinformatics analyses. This work was supported by an AFM-Telethon postdoctoral fellowship and Cure CMD (to D.U.K.); an Ermenegildo Zegna Founder's scholarship (to E.M.); a Canada Research Chair (Tier 2) in Comparative Genomics and an Early Researcher Award from the Ontario Ministry of Research, Innovation and Science (to M.D.W.); and the Canadian Institute for Health Research, Natural Sciences and Engineering Research Council of Canada, the SickKids Foundation, RS McLaughlin Foundation and Women's Auxiliary Chairs (to R.D.C.).

Author information

Affiliations

Authors

Contributions

D.U.K., E.A.I., and R.D.C. conceived the study, designed the experiments, analyzed data, and wrote and edited the manuscript. D.U.K., E.M., E.H., M.D., X.Z., K.M.P., P.B., and Z.B. performed the experiments. A.G.D., D.M., H.Y.X., B.J.F., H.H., and M.D.W. performed bioinformatics analyses. All authors provided feedback and agreed on the final manuscript.

Corresponding authors

Correspondence to Evgueni A Ivakine or Ronald D Cohn.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kemaladewi, D., Maino, E., Hyatt, E. et al. Correction of a splicing defect in a mouse model of congenital muscular dystrophy type 1A using a homology-directed-repair-independent mechanism. Nat Med 23, 984–989 (2017). https://doi.org/10.1038/nm.4367

Download citation

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing